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Understanding complex diseases will benefit the recognition of the properties of the gene networks that control biological
functions. Here, we set out to model the gene network that controls T-cell activation in humans, which is critical for the
development of autoimmune diseases such as Multiple Sclerosis (MS). The network was established on the basis of the
quantitative expression from 104 individuals of 20 genes of the immune system, as well as on biological information from the
Ingenuity database and Bayesian inference. Of the 31 links (gene interactions) identified in the network, 18 were identified in
the Ingenuity database and 13 were new and we validated 7 of 8 interactions experimentally. In the MS patients network, we
found an increase in the weight of gene interactions related to Th1 function and a decrease in those related to Treg and Th2
function. Indeed, we found that IFN-ß therapy induces changes in gene interactions related to T cell proliferation and
adhesion, although these gene interactions were not restored to levels similar to controls. Finally, we identify JAG1 as a new
therapeutic target whose differential behaviour in the MS network was not modified by immunomodulatory therapy. In vitro
treatment with a Jagged1 agonist peptide modulated the T-cell activation network in PBMCs from patients with MS. Moreover,
treatment of mice with experimental autoimmune encephalomyelitis with the Jagged1 agonist ameliorated the disease course,
and modulated Th2, Th1 and Treg function. This study illustrates how network analysis can predict therapeutic targets for
immune intervention and identified the immunomodulatory properties of Jagged1 making it a new therapeutic target for MS
and other autoimmune diseases.
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INTRODUCTION
Understanding the structure and dynamics of biological networks
may prove critical to unravel complex traits and diseases, such as
autoimmune diseases [1]. In the immune response, T cells interact
with antigen-presenting cells in a complex process that generates
changes in gene expression. These changes underlie cell differenti-
ation, and effector and regulatory events, as well as promoting the
acquisition of a panel of adhesion molecules that guide cells to the
appropriate tissues [2, 3]. Several evidences indicates gene de-
regulation within the immune system in autoimmune diseases [4, 5],
such as in Multiple Sclerosis (MS) [6]. Several studies suggest that T-
cell activation and the ensuing differentiation to effector cells or is one
of the most critical process in controlling autoimmunity, as well as
maintaining the balance between effector and regulatory mechanisms
[7–11]. However, despite the many molecular and cellular studies, we
still lack a comprehensive understanding of how the immune system
is controlled and how autoimmune diseases arise. Given the complex
interactions between the cells and molecules that regulate this process,
a systems approach to analyse these processes might identify critical
functional interactions that are disturbed in autoimmune diseases.
Moreover, the identification of such pathological interactions might
facilitate the development of new therapeutic targets [12, 13].
MS is a chronic inflammatory and neurodegenerative disease of
the central nervous system [14]. MS is characterized by the
presence of plaques composed by chronic inflammatory infiltrates,
including T and B cells as well as monocytes into the brain,
accompanied by the presence of large areas of demyelination and
axonal loss [6]. MS is the second cause of permanent disability in
young adults after spinal cord injury and due to its chronic nature
imposes a significant health and social cost in western countries.
Although current immunotherapies are able to modify disease
course, we still need to develop more effective and safe therapies
for improving the quality of life of patients.
The development of network theory is providing important
insights into gene and protein networks [15] . However, the
translation of such advances to humans complex diseases such as
autoimmune diseases is confronted with many challenges, such as
incomplete knowledge of the molecules involved, lack of
quantitative data, the higher degree of complexity and the limited
availability of analytical methods. Among several methods of
network analysis for reconstructing network topology from
experimental datasets [16], Bayesian networks are those that offer
the best results [17, 18]. In human complex diseases, the use of
different clinical phenotypes such as quantitative traits, disease
subtypes or therapies, can introduce meaningful perturbations into
a network to help infer its topology [19].
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The aim of our study was to assess the functional properties of
the gene network that controls the T-cell activation processes in
healthy circumstances and in an autoimmune disease such as MS.
Furthermore, we assessed the effect of immunotherapy in such
a gene network. In addition we were interested in identifying new
therapeutic targets at the systems level. In order to achieve this
objective, we performed a network analysis using quantitative
measurements of gene expression obtained by real time PCR from
a small number of well-known genes involved in T-cell activation,
as well as using prior biological information. We limited our study
to a set of 20 genes for two reasons: 1) we were interested in
obtaining a balanced matrix considering number of genes, subjects
and perturbations; and 2) the limited amount of RNA from every
individual in which assess the gene expression levels by real time
PCR in the same sample. We employed a Bayesian approach to
obtain an accurate reconstruction of the network and indeed, we
assessed the qualitative and quantitative network properties using
several new methods from systems biology. This systems approach
to autoimmunity revealed functional differences in the gene
network that controls T-cell activation that cannot be captured
with previous methods. Moreover, we show how this approach can
be useful in translational clinical research by evaluating the effect
of current therapies, and by identifying new therapeutic targets for
immunotherapy, such as the Jagged1-Notch pathway.
RESULTS
Network analysis of the T-cell activation gene
network
In order to obtain a more accurate network, we decided to focus
on a small set of genes for which the biological information was
more complete, they were previously implicated in MS and having
them distributed among five basic functions associated with T-cell
activation. In this way, we were able to obtain quantitative data
and a good balance between the size of the network and the
number of possible perturbations related to the different disease
phenotypes and therapies [17]. Thus, the experimental dataset was
obtained by assessing the gene expression levels of the 20 genes by
real time PCR in a cohort of 104 subjects, composed by healthy
controls and patients with MS (see Table 1 for details of the
clinical characteristics and Table S1 for statistically summary of
gene expression levels). Our approach profits the presence of
different phenotypes (healthy, patient condition or different
immunotherapies) as perturbations to the system in order to
improve the ability of Bayesian inference to identify the right
interactions. In the other hand, since Bayesian algorithms might
lead to several different results using the same experimental
dataset, we also feed the algorithm with a structural network
template to decrease the number of different outputs and to
Table 1. Demographic and clinical data of patients and
controls
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HC MS
N= 52 52
Male/Female 26/26 26/26
Age (years) 45.6617.7 39.3610.4
EDSS score – 3.0061.82
MSFC score – 20.0260.66
Disease duration (years) – 6.7066.45
Immunomodulatory therapy (yes/no) – 25/27
doi:10.1371/journal.pone.0001222.t001..
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Figure 1. Network analysis of the human T-cell activation network: The structural network was obtained from co-expression analysis using the
Ingenuity database. The structural network has 20 genes and we identified 50 links. Using the structural network as a template and the experimental
dataset (gene expression levels of the 20 genes from 104 subjects quantified by real time-PCR), we reconstructed the T-cell activation network. The
network contains the 20 genes and we identified 31 links (see Table 1 for information about the weight, direction and previous biological knowledge
of the links).
doi:10.1371/journal.pone.0001222.g001
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increase its accuracy. We obtained the template (structural network)
by applying biological knowledge from co-expression studies
available at the Ingenuity database (http://www.ingenuity.com/
). The resulting structural network identified 50 links (Fig 1). Using
this structural network as a template, we inferred the topology of the
human T-cell activation network by using the experimental
dataset performing a Bayesian network approach (see methods).
The inferred network model (Fig 1 and Table 2) has 31 links
between the 20 genes, of which 26 were arcs and 4 were edges. We
found that hubs in the T-cell activation network differ from those
in the structural network, indicating that the experimental dataset
was informative to overcome the literature bias by which genes
studied for many years (e.g. IFNc) are cited more often than new
genes (e.g. transcription factors). Moreover, because cycles are not
permitted in Bayesian networks, the links identified represent
a selection of the most relevant interactions in the network,
including the removal of the redundant ones such as autocrine
loops. Of the 31 links identified, 18 were identified in the gene co-
expression searches in the Ingenuity database, or were described in
the biological literature (supplementary Table S2 and S3) and as
such, they were already present in the structural network. The
remaining 32 links present in the structural network and absent in
the final network were discarded by the algorithm for the following
reasons: 1) the gene interaction is not functional in the tissue
studied (PBMC); 2) the magnitude of the interaction was not
enough for being detected based in the gene co-expression levels;
3) removal of cycles imposed by the Bayesian inference. For 15 of
the 18 predicted links, the direction of the interaction was correctly
inferred, while for the other three interactions there was
insufficient information for the Bayesian algorithm to define this
parameter. The Bayesian algorithm found 13 new links that have
not been previously reported or identified by bioinformatics
analyses of the gene co-expression database. Due to the small size
of our network, we did not calculate common network parameters
such as degree, mean path-length or clustering coefficient.
Validation of the new inferred links
In order to assess the accuracy of our network analysis method and
the validity of our T-cell activation network, we validated the
newly inferred links as well some of the predicted ones in a new
dataset of 16 healthy individuals. In addition, the validation of new
links would probe that differences in the topology of the gene
network have biological implications, at least at the gene
expression level. In vitro assays were performed by stimulating
PBMCs with the recombinant proteins involved in such links (the
parent node), to assess their influence on the target gene (the child
node) in terms of expression. We were able to experimentally
validate the interaction between 7 of the 8 links assessed (87%
validation), defining a statistical association between the levels of
the parent and the child node (Table 3). We found a significant
increase in CD28, IL12A and ITGA4 gene expression after 12 or
24 hours in cells stimulated with IL-10 (p,0.05, Table 3),
validating the predicted arcs IL10–CD28 and IL10–ITGA4, and
the new arc IL10–IL12A. Furthermore, JAG1 gene expression
augmented after 24 hours in IL-4 stimulated cells (p = 0.017),
validating the predicted edge JAG1–IL4. Finally, in CTLA-4 IgG
stimulated cells JAG1, MX1 and PTPRC gene expression all
increased significantly (p,0.05), validating the newly identified
arcs CTLA4–JAG1, and CTLA4–MX1 and the predicted edge
PTPRC–CTLA4. Thus, these results confirm the accuracy of the
reconstructed T-cell activation network.
The topology of the network reveals pleiotropy of
genes in biological functions
We performed a qualitative analysis of the functional properties of
the topology of the network [20, 21] using network analysis [22].
First we obtained the dependence matrix that assesses the role of
every gene in a given function based on the definition of such
function and the constraints imposed by the topology of our
network (Figure 2). We found that the topology of the
reconstructed network identified some of the biological function
of the participating genes, such as the opposing roles of Th1-Th2
activity, as described by the stimulatory effect of IFNG and
TBX21 in Th1 function, and of GATA3 and STAT6 in Th2
Table 2. Gene interactions identified in the T-cell activation
network.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Parent Child Type Relative weight Category Orientation
TGFB1 IL12A Arc 1.00 New –
ITGA4 TGFB1 Arc 0.99 Predicted Reverse
JAG1 IL4 Edge 0.96 Predicted Right
ITGA4 ITGB1 Arc 0.86 Predicted Right
IL4 HLA-DRA Arc 0.78 New –
PTPRC CD28 Arc 0.76 Predicted Reverse
TNF IFNG Arc 0.73 New –
JAG1 TNF Arc 0.68 New –
CTLA4 JAG1 Arc 0.65 New –
STAT1 STAT6 Arc 0.64 Predicted Right
TGFB1 GATA3 Arc 0.61 Predicted Right
IL10 IL12A Arc 0.56 New –
IL12A STAT6 Arc 0.54 New –
ITGA4 STAT1 Arc 0.51 New –
IL4 IL10 Edge 0.49 Predicted Right
STAT1 GATA3 Arc 0.48 Predicted Right
IL12A MX1 Arc 0.46 New –
IL10 CD28 Arc 0.45 Predicted Reverse
TNF ITGA4 Arc 0.43 Predicted Right
GATA3 HLA-DQB1 Arc 0.40 New –
STAT1 TBX21 Arc 0.38 Predicted Right
PTPRC JAG1 Arc 0.37 New –
TGFB1 ITGB7 Edge 0.37 Predicted Right
IFNG HLA-DRA Arc 0.36 Predicted Right
PTPRC CTLA4 Edge 0.35 Predicted Right
ITGA4 ITGB7 Arc 0.33 Predicted Right
TNF STAT1 Arc 0.33 New –
CTLA4 MX1 Arc 0.31 New –
CD28 TNF Arc 0.30 Predicted Right
IL10 ITGA4 Arc 0.30 Predicted Right
JAG1 TBX21 Arc 0.26 Predicted Right
Links whose direction cannot be changed without changing the probabilistic
relations encoded are named arcs, otherwise they are edges. If there is an arc
from gene A to another gene B, then we say that A is a parent of B and B is
a child of A. The relative weight was measured with the Kullback-Leibler (KL)
divergence indicating the contribution of each link with respect to the
complete network structure (see methods). The category indicates whether the
interactions were previously reported in the literature or identified in the co-
expression Ingenuity database (predicted) or not (new). The orientation
indicates if the direction of the causal influence for the predicted interactions
was the same as that in the structural network (right) or the opposite (reverse).
doi:10.1371/journal.pone.0001222.t002..
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function, as well as by the inhibitory effect of IFNG and TBX21 in
Th2 function, and of GATA3 and STAT6 in Th1 function
(Figure 2). Indeed, the topological analysis identified HLA
molecules as activators in the antigen presentation process and
the role of CTLA4, IL-10, TGFß and JAG1 in Treg function.
Moreover, the dependence matrix also highlighted the pleiotropic
activity of many genes in T-cell activation, as represented by the
dual role (in yellow) of several genes in the majority of the
functions analyzed. In fact, the majority of the genes were
activators of migration, indicating that the expression of adhesion
molecules by T cells must be regulated after activation so that they
may migrate and act in the target tissue. Furthermore, MX1 was
included to assess the effect of IFN-ß therapy, although it does not
influence T-cell activation, and we found that it did not affect the
dependency matrix of the T-cell activation network, reinforcing
the specificity of the analysis. However, the small size of the
network and limitation of the network analysis process might
prevent the right identification of the implication of every single
gene in the functions studied, exemplified by the fact that in some
cases the Cell Net Analyzer (CNA, see methods) was not able to
discriminate a stimulatory or inhibitory effect and release a dual
influence (yellow) or no influence (white) for a given gene. We
identified the minimal cut sets (MCS, see methods) for each
function in order to assess the structural robustness and fragility of
the given function (Table 4). We found that the process of T-cell
activation was very robust (robustness = 1, Table 4), mainly due to
the selection of the genes critical for this process. Migration
displayed an intermediate robustness (robustness = 0.58, Table 4)
because most of the genes contribute to generate a specific pattern
of adhesion molecule expression after T-cell activation. In
contrast, Th1-Th2 and Tr function were not very robust
(robustness = 0.27 and 0.21 respectively, Table 4), indicating that
T-cell fate after activation is less fixed and that it is more sensitive
to stochastic events or environmental signals [2].
Differences in the T-cell activation network between
healthy individuals and patients with Multiple
Sclerosis
To quantify the importance of each interaction of the network in
healthy controls, MS patients and MS patients treated with INF b,
we calculated the Kullback-Leibler divergence (KL-divergence) of
each interaction of the network for each diagnosis. To do that, we
used the inferred topology of the network of T-cell activation and
the gene expression levels of each of the groups (see methods).
Thus, we obtained quantitative values that describe the behaviour
of each interaction of the T-cell activation network under the
different diagnosis. These values are indicative of the importance
of the interaction, or to put it another way, they are indicative of
the activation of that interaction. We found that the weight of
some gene interactions differed in the two networks (Figure 3A
represented by the colour of the arrow; Table 5). Accordingly, we
found a significant decrease in the weight of the interaction
between JAG1–IL4, IL10–IL12A, and IL12A–STAT6 in patients
with MS (p,0.05), and a significant increase in the weight of the
interaction between TGFB1–IL12A and PTPRC–JAG1 when
compared to HC (p,0.05).
Effect of immunotherapy in the T cell activation
network
Because immunomodulatory treatments might exert their activity
in a pleiotropic manner, we were interested in evaluating the effect
of one of the therapies for MS in the network, such as INF-ß
therapy. Our aim was to identify the functions targeted by IFN-ß
in order to validate our approach to study immunotherapies at the
systems level. Following the same procedure, we reconstructed the
T-cell activation network using the gene expression levels from
IFN-ß treated and untreated patients, and we compared the
differences in interaction weight between pairs of genes (Figure 3B).
When the IFN-ß treated and untreated patients were compared,
we found a significant increase in the weight of the interaction
between ITGA4–TGFB1 and IL4–HLA-DRA (p,0.001) and
a significant decrease in the weight of the interaction between
JAG1–TNF, TGFB1–GATA3, IL10–IL12A, IL10–CD28,
TGFB1–ITGB7, ITGA4–ITGB7 and IL10–ITGA4 (p,0.005,
Table 5). Thus, our results indicate that IFN-ß modifies different
regions of the T-cell activation network, affecting different
functions and thereby confirming its pleiotropic activity. While
we identified the immunomodulatory effect of IFN-ß therapy in
the T-cell activation network, we found that it did not restore their
interaction weight to the baseline levels represented by the HC
network (Figure 3C). Hence, IFN-ß therapy fails to completely
restore the T-cell activation network indicating that this therapy is
unable to completely normalize T cell function. This is in
agreement with the clinical experience that IFN-ß therapy is only
partially effective in MS [23].
We were also interested in identifying new therapeutic targets
not addressed by IFN-ß therapy. Thus, we analyzed the
differences between the HC and the IFN-ß treated patient
networks. Ideally, a therapy will restore the functional state close
to that of the healthy gene network and any deviation from such
state can be considered as a therapeutic target [12]. The
comparison between IFN-ß treated patients and HC networks
Table 3. Validation of the gene interactions in the T-cell
activation network.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stimulus
Target
Gene
Gene Expression levels (mean (SD) ct
value) p value
0 hours 12 hours 24 hours
IL10 CD28 1.49E+01 1.14E+02 1.65E+02 ,0.001a
(1.25E+01) (1.18E+02) (1.43E+02) ,0.001b
IL12A 3.15E+00 2.32E+01 3.54E+00 0.017a
3.99E+00 (3.30E+01) (3.27E+00)
ITGA4 6.72E+02 2.69E+03 2.60E+03 0.006a
(8.22E+02) (5.45E+03) (2.59E+03) ,0.001b
IL4 HLA-DRA 3.20E+02 ND 9.46E+02 ns
(2.92E+02) (2.06E+03)
JAG1 1.64E-01 ND 5.55E-01 0.017b
(9.38E-02) (5.90E-01)
CTLA4 JAG1 1.64E-01 ND 1.11E+00 ,0.001b
(9.38E-02) (2.15E+00)
MX1 2.27E+01 ND 1.03E+02 0.045b
(1.98E+01) (1.76E+02)
PTPRC 2.67E-01 ND 7.50E-01 0.020b
(1.58E-01) (1.37E+00)
Gene expression levels of target genes were assessed by real time PCR in PBMCs
from 16 new healthy controls after stimulation with IL10, IL4 or CTLA4
(stimulus) for 12 to 24h. Results are described as the mean (SD) of the normalize
ct value from real time PCR assays. Differences were assessed with the Mann-
Whitney U test.
ND: not done; ns: not significant; ap value comparing results at 0 to 12 hours; bp
value comparing results at 0 to 24 hours
doi:10.1371/journal.pone.0001222.t003..
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(Figure 3C, Table 5) showed a significant increase in the weight of
the gene interaction between the ITGA4–TGFB1, and the
PTPRC–JAG1 genes (p,0.05) and a decrease in the weight of
the interactions between JAG1–IL4, JAG1–TNF, TGFB1–
GATA3, IL10–IL12A, IL12A–STAT6, IL10–CD28, TGFB1–
ITGB7, ITGA4–ITGB7 and IL10–ITGA4 (p,0.05). Overall, we
found that IFN-ß therapy failed to restore the balance between
pro-inflammatory cytokines and Treg function. Pro-inflammatory
cytokines, such as TNF or IL12A, the T-cell activation molecule
CD28, the regulatory molecules IL10, TGFB1 or the adhesion
molecules ITGA4 and ITGB1 have all been evaluated previously
as therapeutic targets for autoimmune diseases, including MS [24–
29]. Hence, we focused on the JAG1 gene as a potential target for
new therapies to treat autoimmune diseases. JAG1 plays a critical
role in our network since it was consistently modified in the disease
state and its interactions were almost unmodified by IFN-ß
therapy, making it an excellent therapeutic target in our model,
even if JAG1 mRNA levels were not significantly different between
patients and controls (Table S1). Moreover, JAG1 has recently
being identified as a candidate gene for MS [30].
Figure 2. Network Analysis: Dependence matrix. The role of each gene in every T-cell activation function (antigen (Ag) presentation; Th1
differentiation; Th2 differentiation; Treg function; migration) based on the topology of the network is displayed using the following colour code:
yellow: dual role (activator or inhibitor); green: full activator; red: full inhibitor; white: no influence.
doi:10.1371/journal.pone.0001222.g002
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Validation of JAG1 as a therapeutic target in
Multiple Sclerosis
Notch signalling in the adult immune system has several functions
depending on the ligand involved [31, 32]. Jagged1 signalling
promotes Treg function whereas Delta1 promotes pro-inflamma-
tory responses. In order to validate the JAG1 gene and its protein
jagged1 as a therapeutic target, first we assessed the effect of
stimulating human PBMCs from MS patients in vitro with
a Jagged1 peptide agonist [33]. We used the HES5 and MX1
genes as reporters of the Jagged1-Notch pathway and of the IFN-
ß-IFNR1 pathway, respectively. Accordingly, PBMCs cultures
stimulated with either the Jagged1 peptide agonist or IFN-ß
displayed a significant increase in HES5 or MX1 gene expression
(Supplementary Table S4). Moreover, the Jagged1 stimulated
network differed from the untreated and the IFN-ß treated
network (Table 6, Fig 4A). Compared to the network from
untreated patients, Jagged1 therapy induced an increase in the
interaction weight between JAG1-TNF and the downstream
interaction TNF-IFNG, as well as a decrease in the interaction
weight between CD28-TNF (Figure 4A). Thus, our network
analysis was able to capture the biological effect of Jagged1-Notch
signalling in T-cell activation. Our results suggested that the
Jagged1-Notch pathway modulates Th1 function. Exposure of
PBMCs from untreated patients to IFN-ß in vitro yielded a network
similar to that obtained ex-vivo from IFN-ß treated patients
(Figure 3B and 4B), although some quantitative differences in
the interaction weight between the pairs of genes involved in the
effect of IFN-ß were detected. Indeed, IFN-ß therapy impaired the
effect of JAG1 on TNF that is required for Jagged1 to suppress
Th1 function in our model. Finally, the combination of Jagged1
and IFN-ß treatment indicates a synergistic effect of both therapies
(Table 6, Fig 4C), and the effect of each therapy could be
identified in the different network interactions, which might
produce different functional effects. Moreover, Jagged1 therapy
was able to recover the effect of JAG1 on TNF that was lost with
Table 4. Network Analysis: Minimal cut-set analysis (MCS).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cellular process Fragility Robustness MCS
Ag presentation
and co-
stimulation
0 1 none
Th1 and Th2
differentiation
0.73 0.27 (JAG1, TNF) (CD28,JAG1)
(IL4 TBX21 TNF)
(ITGA4, IFNG, JAG1,STAT1)
(IFNG, JAG1, STAT1, TGFB1)
(ITGA4, IFNG, IL4, STAT1, TBX21)
(IFNG, IL4, STAT1, TBX21, TGFB1)
(GATA3, IFNG, IL12A, JAG1, STAT1)
(GATA3, IFNG, IL12A, IL4, STAT1,
TBX21)
Treg function 0.79 0.21 (CTLA4, JAG1, TNF)
(CTLA4, CD28, JAG1)
(CTLA4, IL4, TBX21, TNF)
(CTLA4, ITGA4, IFNG, JAG1, STAT1)
(CTLA4, IFNG, JAG1, STAT1, TGFB1)
(CTLA4, ITGA4, IFNG, IL4, STAT1,
TBX21)
(CTLA4, IFNG, IL4, STAT1, TBX21,
TGFB1)
Migration to
tissues
0.42 0.58 (ITGA4)
(IL10, TNF)
(JAG1, TNF)
(CD28, JAG1)
(IL4, TNF)
doi:10.1371/journal.pone.0001222.t004..
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Figure 3. Comparison of the T-cell activation network between patients and controls. A) HC versus untreated MS patients; B) untreated MS
patients versus MS patients treated with IFN-ß; C) HC versus patients treated with IFN-ß. Comparisons between gene interaction weights are
described using the following colour code: black: no change; green: decreased; red: increased. See Table 4 for statistical analysis.
doi:10.1371/journal.pone.0001222.g003
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Table 5. Comparison in the weight of the interaction in the T-cell activation network between controls, MS patients and MS
patients treated with IFN-ß.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene interaction KL value
Parent Child HC MS MS IFN-ß p
TGFB1 IL12A 0.28 (0.11–0.48) 0.62 (0.35–0.90) 0.45 (0.03–0.60) 0.003a
ITGA4 TGFB1 0.30 (0.03–0.49) 0.19 (0.04–0.55) 0.99 (0.58–1.00) ,0.001b
,0.001c
JAG1 IL4 0.58 (0.41–1.00) 0.28 (0.10–0.52) 0.27 (0.02–0.56) 0.012a
0.008c
ITGA4 ITGB1 0.21 (0.07–0.48) 0.31 (0.13–0.35) 0.55 (0.07–0.99) ns
IL4 HLA-DRA 0.34 (0.03–0.63) 0.22 (0.11–0.30) 0.47 (0.18–0.68) 0.001b
PTPRC CD28 0.32 (0.16–0.47) 0.33 (0.16–0.69) 0.12 (0.03–0.85) ns
TNF IFNG 0.26 (0.16–0.46) 0.36 (0.12–0.62) 0.23 (0.06–0.61) ns
JAG1 TNF 0.36 (0.24–0.60) 0.52 (0.19–0.68) 0.10 (0.00–0.37) 0.006b 0.012c
CTLA4 JAG1 0.25 (0.12–0.52) 0.53 (0.23–0.61) 0.40 (0.08–0.59) ns
STAT1 STAT6 0.22 (0.00–0.61) 0.32 (0.12–0.94) 0.43 (0.02–0.67) ns
TGFB1 GATA3 0.39 (0.09–0.47) 0.18 (0.04–0.29) 0.00 (0.00–0.04) ,0.001b
,0.001c
IL10 IL12A 0.36 (0.19–0.59) 0.07 (0.00–0.15) 0.00 (0.00–0.03) ,0.001a
0.031b
,0.001c
IL12A STAT6 0.39 (0.12–0.79) 0.06 (0.00–0.23) 0.12 (0.00–0.25) 0.001a
0.008c
ITGA4 STAT1 0.25 (0.05–0.64) 0.20 (0.01–0.37) 0.54 (0.00–0.62) ns
IL4 IL10 0.22 (0.07–0.51) 0.10 (0.00–0.28) 0.05 (0.00–0.14) ns
STAT1 GATA3 0.31 (0.09–0.53) 0.29 (0.12–0.49) 0.35 (0.00–0.41) ns
IL12A MX1 0.22 (0.03–0.69) 0.22 (0.04–0.32) 0.10 (0.00–0.36) ns
IL10 CD28 0.23 (0.06–0.41) 0.12 (0.10–0.53) 0.03 (0.00–0.07) 0.043b
,0.001c
TNF ITGA4 0.23 (0.14–0.31) 0.36 (0.01–0.67) 0.14 (0.07–0.53) ns
GATA3 HLA-DQB1 0.24 (0.06–0.46) 0.05 (0.01–0.33) 0.16 (0.00–0.37) ns
STAT1 TBX21 0.30 (0.08–0.55) 0.23 (0.17–0.53) 0.20 (0.00–0.66) ns
PTPRC JAG1 0.13 (0.01–0.22) 0.24 (0.15–0.33) 0.39 (0.14–0.69) 0.048a
0.011c
TGFB1 ITGB7 0.27 (0.02–0.36) 0.44 (0.21–0.60) 0.00 (0.00–0.00) ,0.001b
,0.001c
IFNG HLA-DRA 0.23 (0.00–0.53) 0.21 (0.03–0.29) 0.20 (0.15–0.39) ns
PTPRC CTLA4 0.19 (0.05–0.36) 0.04 (0.00–0.31) 0.06 (0.01–0.46) ns
ITGA4 ITGB7 0.15 (0.00–0.38) 0.30 (0.03–0.41) 0.00 (0.00–0.00) ,0.001b
0.007c
TNF STAT1 0.37 (0.07–0.59) 0.19 (0.00–0.29) 0.35 (0.00–0.41) ns
CTLA4 MX1 0.28 (0.01–0.43) 0.11 (0.01–0.40) 0.07 (0.00–0.22) ns
CD28 TNF 0.12 (0.02–0.35) 0.14 (0.03–0.24) 0.21 (0.00–0.44) ns
IL10 ITGA4 0.32 (0.16–0.39) 0.34 (0.20–0.72) 0.00 (0.00–0.09) ,0.001b
,0.001c
JAG1 TBX21 0.22 (0.11–0.43) 0.06 (0.01–0.24) 0.15 (0.01–0.44) ns
ns: not significant
ap value between HC and MS patients
bp value between MS patients and MS patients treated with IFN-ß
cp value between HC and MS patients treated with IFN-ß
Using the Kullback-Leibler (KL) divergence of links, we compared the differences between the control (HC), untreated MS patients (MS) and MS patients treated with
IFN-ß (MS IFN-ß) networks. The results are described by the median (range) of the KL value. p values were adjusted using the Bonferroni method.
doi:10.1371/journal.pone.0001222.t005..
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Table 6. Comparison in the weight of the interaction in the T-cell activation network between jagged1, IFN-ß and jagged1 plus
IFN-ß treatments in vitro.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gene interaction
KL value
Parent Child Basal Jagged1 IFN-ß Jagged1+IFN-ß p value
TGFB1 IL12A 0.02 (0.00–0.04) 0.02 (0.01–0.04) 0.09 (0.02–0.15) 0.08 (0.06–0.11) ,0.001b
,0.001c
ITGA4 TGFB1 0.03 (0.01–0.05) 0.03 (0.01–0.04) 0.09 (0.02–0.15) 0.08 (0.02–0.13) ,0.001b
,0.001c
JAG1 IL4 0.04 (0.01–0.07) 0.02 (0.00–0.04) 0.03 (0.00–0.05) 0.03 (0.00–0.05) ns
ITGA4 ITGB1 0.01 (0.00–0.01) 0.00 (0.00–0.01) 0.12 (0.04–0.21) 0.14 (0.09–0.18) ,0.001b
,0.001c
IL4 HLA-DRA 0.11 (0.06–0.16) 0.10 (0.07–0.13) 0.13 (0.05–0.22) 0.13 (0.02–0.24) ns
PTPRC CD28 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
TNF IFNG 0.00 (0.00–0.00) 0.02 (0.00–0.05) 0.00 (0.00–0.00) 0.05 (0.00–0.11) ,0.001a
,0.001c
JAG1 TNF 0.03 (0.01–0.05) 0.09 (0.01–0.18) 0.02 (0.01–0.03) 0.20 (0.02–0.41) 0.014a
0.047b
0.004c
CTLA4 JAG1 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
STAT1 STAT6 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.01 (0.00–0.02) 0.01 (0.00–0.02) 0.031b
0.045c
TGFB1 GATA3 0.15 (0.08–0.22) 0.12 (0.08–0.16) 0.13 (0.10–0.17) 0.16 (0.06–0.26) ns
IL10 IL12A 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
IL12A STAT6 0.01 (0.00–0.02) 0.01 (0.00–0.03) 0.04 (0.01–0.07) 0.13 (0.12–0.14) ,0.001b
,0.001c
ITGA4 STAT1 0.02 (0.01–0.04) 0.02 (0.01–0.03) 0.05 (0.01–0.09) 0.06 (0.04–0.08) ,0.001b
,0.001c
IL4 IL10 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
STAT1 GATA3 0.06 (0.01–0.11) 0.02 (0.07–0.12) 0.02 (0.01–0.04) 0.02 (0.07–0.1) ns
IL12A MX1 0.01 (0.00–0.01) 0.00 (0.00–0.01) 0.01 (0.00–0.03) 0.03 (0.02–0.04) ,0.001b
,0.001c
IL10 CD28 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
TNF ITGA4 0.00 (0.00–0.00) 0.00 (0.00–0.01) 0.01 (0.00–0.01) 0.00 (0.00–0.01) ns
GATA3 HLA-DQB1 0.07 (0.03–0.1) 0.05 (0.01–0.11) 0.08 (0.02–0.14) 0.13 (0.08–0.18) ns
STAT1 TBX21 0.24 (0.15–0.33) 0.20 (0.14–0.26) 0.20 (0.15–0.24) 0.22 (0.09–0.35) ns
PTPRC JAG1 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
TGFB1 ITGB7 0.06 (0.02–0.09) 0.07 (0.03–0.10) 0.12 (0.07–0.18) 0.17 (0.07–0.27) ,0.001b
,0.001c
IFNG HLA-DRA 0.12 (0.09–0.15) 0.16 (0.09–0.24) 0.18 (0.08–0.27) 0.10 (0.03–0.16) ns
PTPRC CTLA4 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
ITGA4 ITGB7 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
TNF STAT1 0.01 (0.01–0.02) 0.01 (0.00–0.01) 0.01 (0.00–0.01) 0.03 (0.00–0.05) ns
CTLA4 MX1 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
CD28 TNF 0.02 (0.01–0.03) 0.00 (0.00–0.01) 0.02 (0.00–0.03) 0.00 (0.00–0.01) ,0.001a
,0.001c
IL10 ITGA4 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) ns
JAG1 TBX21 0.06 (0.03–0.09) 0.06 (0.02–0.11) 0.09 (0.04–0.14) 0.04 (0.02–0.07) ns
ns: not significant
ap value between basal and Jagged 1
bp value between basal and IFN-ß
cp value between basal and Jagged1+IFN-ß
Using the Kullback-Leibler (KL) divergence of links, we compared the differences from in vitro assays in the interaction weight between pairs of genes using PBMCs from
untreated patients that were stimulated with either the jagged1 agonist peptide, IFN-ß or Jagged1 plus IFN-ß. Results are described as the median (range) of the K-L
value. p values were adjusted using the Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0001222.t006..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Netowrk Analysis Autoimmunity
PLoS ONE | www.plosone.org 8 November 2007 | Issue 11 | e1222
IFN-ß therapy, suggesting that this combined therapy will
maintain the Th1 function suppression induced by Jagged1.
In order to confirm the results from our network analysis, we
evaluated the effect of the Jagged1 agonist peptide in the animal
model of MS. C57B6 mice immunized with MOG35–55 peptide
were treated with the Jagged1 peptide i.p. from day 0 to day 30
and this produced a milder progression of the disease (Figure 5A)
and lower histological scores (Figure 5B and 5C) than in placebo
animals. Hence, Jagged1-Notch signalling appears to exert an
immunomodulatory effect in brain autoimmunity. We studied the
possible mode of action of Jagged1 therapy by assessing several
immune responses involved in autoimmunity. In addition, we
tested the in vivo effect of Jagged1 therapy in the genes of the T-cell
activation network. Previous studies suggested a role for Jagged1-
Notch signalling in promoting Treg and Th2 function [31]. We
found that by day 9 after immunization, animals treated with
Jagged1 peptide have increased percentage of CD25+Foxp3+ cells
that placebo animals (21.6% compared to 13.6%, p = 0.032;
Fig. 5D) and such differences were lost by day 30 (Fig. 5D). In
addition, we also found that by day 9 after immunization, Jagged1
treated animals have significant higher numbers of Th2 cells (IL-4
secreting cells; p = 0.032) and a trend for decreased numbers of
Th1 cells (IFNc secreting cells; p = 0.056) than placebo animals,
and not changes in numbers of IL-17 secreting cells (Fig. 5E). By
day 30, differences were lost and frequency of such populations
were similar between Jagged1 and placebo treated animals (data
not shown). We also analyzed the effect of Jagged1 peptide therapy
in gene expression levels in splenocytes by day 9 and 30 after
immunization. We found that by day 9 p.i. Jagged1 treated
animals have increased gene expression levels of IL-10 (p = 0.029)
and decreased levels of TNFa and IL-17a (p,0.05 in both cases,
Fig. 5F and Table S5). By day 30, we found a decrease in TGFß1,
TNFa, and ITGB7 gene expression levels in animals treated with
Jagged1 when compared with untreated animals (p,0.05 in all
cases; Table S5). These results might suggest that Jagged1-Notch
signalling promotes Treg and Th2 responses and suppress Th1
function. Thus, our findings indicate that the Jagged1-Notch
pathway may be a therapeutic target to treat MS and other
autoimmune diseases. Moreover, our network approach allowed
us to predict a mechanism of action that was not expected from
previous biological knowledge.
DISCUSSION
In the present study we have provided proof of concept that a gene
network analysis approach is feasible to study human systems and
diseases, providing valuable information about the complex
interactions involved in biological process and in complex diseases.
This is important since most systems biology studies have been
applied to lower organisms and its application to higher animals
and humans has been restricted by the lack of biological
knowledge, technological and analytical tools, as well as by the
higher degree of complexity of such organisms. Biological
functions, as well as complex traits and diseases, can only rarely
be attributed to an individual molecule. On the contrary, complex
interactions between dozens of molecules lead to a specific
biological function [34], and altering the relationships between
these elements may disrupt the activity in such systems. Network
analysis has emerged as a powerful tool to understand complex
intercellular interactions that contribute to the structure and
function of living systems [1] and it can be used to study complex
traits and diseases in order to discover new therapies [35, 36].
Indeed, the application of a Bayesian approach to define cell
networks has been successfully used and as well as to infer classic,
well understood signalling networks [37]. Such an approach has
also provided new insights into specific systems that have not been
previously identified through hypothesis-directed research [17].
In our network analysis, we identified 31 interactions between
20 genes acting in the immune system of which, 18 were predicted
either from the literature or by bioinformatics analysis of co-
expression databases. However, the other 13 interactions were
new and had not been predicted using bioinformatics strategies.
These latter interactions could be more specific for autoimmunity
Figure 4. Comparison of the T-cell activation network after in vitro stimulation with jagged1, IFN-ß or Jagged1+IFN-ß: A) untreated patients
versus stimulation with the Jagged1 agonistic peptide for 24 h; B) untreated patients versus stimulation with IFN-B for 24 h; C) untreated patients
versus stimulation with JGA1+IFN- ß for 24 h. Comparisons between gene interaction weights are described using the following colour code: black:
no change; green: decreased; red: increased. See Table 5 for statistical analysis.
doi:10.1371/journal.pone.0001222.g004
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such that our experimental dataset from patients suffering an
autoimmune disease was informative to highlight the importance
of these interactions when compared to the healthy state. It must
to be remembered that the gene interactions identified in our
network does not mean that they are direct molecular interactions
and intermediary molecules might account for such effect. Indeed,
among the many interactions between the genes in our network,
we were able to identify either the most robust or the ones that in
the specific condition we are studying (MS) are most relevant,
implying that some others could be missed for our analysis, even if
they have been biologically demonstrated. The validation of the
majority of these interactions, both the predicted and new
Figure 5. Validation of Jagged1 as a therapeutic target in the animal model of MS: C57B6 mice (n = 60) were immunized with MOG35–55 and
treated with Jagged1 agonist peptide i.p. (n = 30) or placebo (n = 30) from day 0 to day 30 in two different experiments. Twelve animals (6 from each
treatment group) were sacrificed by day 9 in order to perform immunological studies. Animals treated with the Jagged1 agonist peptide have
a clinical (A) and histological (B) score lower than placebo animals. C) Representative spinal cord sections from placebo (a) and jagged1 (b) treated
animals stained with Luxol-fast blue showing a decrease in the presence of inflammatory infiltrates and the extend of demyelination in the Jagged1
treated animals. FACS analysis assessing the percentage of CD25+Foxp3+ Treg cells (D) ELISPOT studies assessing the in vitro secretion of Th1 (INFc),
Th2 (IL-4) and Th17 (IL-17) cytokines (E) and real-time PCR (F) studies in splenocytes from Jagged1 treated and untreated mice. D) Mice treated with
Jagged1 peptide have higher percentage of Treg cells than placebo animals by day 9 p.i. (p = 0.032), and such difference disappeared by day 30. E)
Splenocytes from Jagged1 treated mice expressed higher levels of IL-4, lower levels of IFNc and similar levels of Il-17 than placebo animals at day 9
p.i. F) Jagged1 treated animals expressed higher levels of IL-10 and lower levels of TNFa and IL-17 than placebo animals at day 9 p.i. Results are
expressed as the mean6SEM
doi:10.1371/journal.pone.0001222.g005
Netowrk Analysis Autoimmunity
PLoS ONE | www.plosone.org 10 November 2007 | Issue 11 | e1222
interactions, indicates that our approach was sufficiently powerful
and accurate to identify true gene interactions in human cells. In
addition, the validation of new gene interactions indicates that
differences in gene interaction weight have biological implications,
at least at the gene expression level. The high validation rate was
due to the balanced design between the number of genes studied,
the use of accurate quantitative methods and the biological
knowledge available in the literature, as well as benefiting from the
use of system biology methods such as Bayesian inference,
previously validated in other settings. In addition, in the majority
of the cases we were also able to correctly identify the direction of
the interactions. Identifying the direction of an interaction is an
important step in reverse network engineering and requires larger
datasets for network inference [17]. Although we use a mixed cell
population such as PBMCs, our results indicates that the network
analysis was able to identify the contribution of every gene to the T
cell activation process, which is a multicellular process by
definition implying antigen presenting cells and T cells. Finally,
the qualitative analysis of the network using CNA shows that our
method was able to identify a network topology, which is related
with the biological functions involved. This analysis was more an
attempt to confirm the influence of network topology in biological
functions even if such analysis was limited by the size of our
network and was not able to predict all functions studied (e.g. the
role of IL-4 in Th2). Thus, our results suggest that the
reconstruction of biological networks from experimental data is
a feasible strategy to study human system and diseases.
Biological networks are robust [1], and we predicted that the
differences between the healthy and disease state for complex and
polygenic disease would not be based on the deletion of nodes
(genes or proteins) or even links (gene or protein interactions), but
rather in more subtle changes in the weight of the interactions. For
this reason we were more interested in performing a quantitative
analysis of the network than in the topological differences between
such networks. Our quantitative analysis of the network that
controls T-cell activation revealed several significant differences
between the healthy state and MS. MS is an inflammatory disease
in which T-cell activation is dysfunctional [6] and regulatory T cell
function is impaired [38]. The comparison between the T-cell
activation networks from HC and MS patients showed an overall
decrease in the activity (defined here by the change in the weight
of the interaction between pair of genes) of Treg and Th2 function,
and an increase in Th1 activity. For example, JAG1 constitutes an
instructive signal for Th2 differentiation by inducing GATA3 and
by directly regulating IL4 gene transcription [39]. Thus, the
reduction in the weight of the JAG1–IL4 gene interaction in the
MS patient network indicates a decrease in Th2 differentiation.
Furthermore, the reduced weight of the IL12A–STAT6 in-
teraction also suggests diminished Th2 differentiation due to the
fact that STAT6 plays a central role in exerting IL4 mediated
biological responses [40] and IL12 is important in the regulation of
the Th2 response [41]. Indeed, a reduction in the weight of the
IL10–IL12A interaction indicates a decrease in the suppression
mediated by IL-10 over Th1 function [42]. On the other hand, an
increase in the weight of the TGFB1–IL12A and PTPRC–JAG1
interactions suggests more pronounced Th1 activity in patients
with MS. IL12 is required for the induction of IFNc and PTPRC
induces the expression of TNFa [43], which can stimulate cell
proliferation via Jagged1 [44]. Thus, our results identify JAG1 and
IL12A as critical genes in the pathogenesis of MS. IL12 plays
a central role in brain autoimmunity [45] and recent genetic
studies have associated JAG1 to MS susceptibility [30]. Of course,
several other genes not included in our study may play a role in the
pathogenesis of MS, but our results indicate that even using a small
set of genes, a quantitative network analysis is able to identify
functional differences between healthy and disease states.
Moreover, we show that a quantitative network analysis
provides valuable information about how therapies work at
a system level, showing that in most cases they exert a pleiotropic
activity that is difficult to capture in single molecule assays. But
more importantly, our approach allowed us to identify new
therapeutic targets that are not modified by current therapies,
based on the quantitative changes in the network produced by the
disease. Current immunotherapies for autoimmune diseases such
as interferon beta, glatiramer acetate or natalizumab exert their
action through pleiotropic activities that are poorly understood
[46]. In our study, the increase in the weight of the ITGA4–
TGFB1 interaction and the decrease in weight of the JAG1–TNF,
TGFB1–GATA3, IL10–CD28, TGFB1–ITGB7, ITGA4–ITGB7
and IL10–ITGA4 interactions in patients treated with IFN-beta
when compared with untreated MS patients and HC, suggest
a direct influence of IFN-ß on these pathways. The decrease in the
weight of the JAG1–TNF, TGFB1–GATA3 and IL10–CD28
interactions support the idea that IFN-ß activity involves the
suppression of T cell proliferation, the induction of Th2 cytokine
production, inhibition of Th1 cytokine production and inhibition
of monocyte activation [47]. Also, the changes in the links
involving the adhesion molecules ITGA4, ITGB1 and ITGB7
confirm the role of IFN-ß treatment in decreasing the surface
expression of adhesion molecules, which reduces the migratory
potential of T cells [48]. The in vitro validation of the IL10–IL12A
interaction deserves special mention, as it suggests that IFN-ß
affects this pathway. However, based on our analysis, IFN-ß
therapy failed to restore such an interaction to the normal levels in
the healthy state. Indeed, differences in the weight of the JAG1–
IL4, IL12A–STAT6 and PTPRC–JAG1 interactions in treated or
untreated MS patients compared with HC would suggest that
IFN-ß treatment has no effect on these pathways and as such, they
may be considered as novel therapeutic targets. Taking into
account that JAG1 seems to be involved in the genetic
susceptibility of MS, its role in the immune system, and the
failure of IFN-ß treatment to modulate its function, we propose
JAG1 as a new therapeutic target in the treatment of the MS.
As a proof of concept that network analysis might identify
valuable therapeutic targets, we validated the Jagged1-Notch
pathway as a therapeutic target for MS. The Notch pathway exerts
several activities in the developing, as well as in the mature
peripheral immune system [31]. The outcome of Notch signalling
depends on the ligand involved and accordingly, it has been shown
that Jagged1 activates Treg and Th2 function whereas Delta1
promotes the Th1 response. We were able to demonstrate that
treating immune cells from patients with MS with an agonistic
peptide of Jagged1 in vitro modulates the T-cell activation network,
mainly suppressing Th1 function (represented by the strong effect
of JAG1 over TNF and the downstream effect of TNF on IFNG).
Interfering with Jagged1 has been shown to suppress IFNc
production by dendritic cells [49]. Moreover, we found that IFN-ß
and Jagged1 therapy exerted a synergy in vitro. In our network
analysis we were able to identify the individual and non-
overlapping effects of both therapies and the predominant role
of Jagged1 in suppressing Th1 activation, overcoming the
suppressor effect of IFN-ß therapy on the JAG1-TNF interaction.
Finally, we were able to identify the therapeutic potential of the
Jagged1-Notch pathway in the animal model of MS, confirming its
immunomodulatory effect. We found that Jagged1-Notch signal-
ling enhances Treg and Th2 function and suppressed Th1
function in mice suffering an autoimmune disease. Although we
found no effect of Jagged1 therapy in Th-17 subset (no changes in
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levels of secreted IL-17 in the ELISpot assays), indirect evidence
might suggest that Jagged1 might influence also this function, since
critical molecules for Th-17 induction were modified by Jagged1
therapy at the RNA level such as IL17a, TNFa and TGFß.
Finally, it has been described that Notch signalling in MS brains
might contribute to failure of regenerative process [50]. We found
no evidences that treating animals with an agonistic peptide of
Jagged1 might impair recovery for EAE. However, further studies
will be required to fully validate the therapeutic opportunities
associated with the Jagged1-Notch pathway in autoimmune
diseases, mainly considering the critical and pleiotropic functions
that this pathway plays in many cell types that might lead to
undesired side effects.
In summary, our results suggest that a quantitative network
approach is a useful tool in medicine to understand complex
diseases and discover new therapeutic targets. In particular, the
Jagged1-Notch pathway seems to be a good candidate to
participate in the susceptibility and therapy of MS. Hence, a more
profound study of its regulation may help to understand its
implication in MS and its potential for therapy.
METHODS
Human subjects and biological assays
1. Human subjects We studied 52 patients with MS [51] and
52 sex and age matched healthy controls (HC) from the same
population with no history of autoimmune diseases. For validation
assays of the identified links in the network we used a second set of
16 healthy individuals. For the in vitro assays with PBMCs for
testing the role of Jagged1 peptide and IFNB, we used a new set of
24 patients with MS that were not receiving immunomodulatory
therapy. The demographic and clinical data from the subjects are
shown in Supplementary Table S1. Patients were recruited by
their neurologist after obtaining written informed consent. This
study was approved by the Institutional Review Board at the
University of Navarra.
2. RNA extraction, probes and rtPCR Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll-Paque
(Pharmacia Biotech) and they were immediately submerged in
RNAlater RNA Stabilization Reagent (Qiagen) to preserve the
gene expression patterns. Total RNA was isolated using the
RNeasy Mini Kit (Qiagen), removing DNA with the RNase-Free
DNase Set (Qiagen), and the High-Capacity cDNA Archive Kit
(Applied Biosystems) was used to synthesise cDNA from the total
RNA. Primer sequences and target-specific fluorescence-labelled
TaqMan probes were purchased from Applied Biosystems
(TaqMan Gene Expression Assays, Supplementary Table S2).
Quantitative real-time PCR (rt-PCR) was performed with the
DNA Engine Opticon2 (MJ Research). Each sample was run in
triplicate and the target and endogenous control gene were
amplified in different wells on each plate. We used GAPDH and
B2M as controls because both genes were described as a good
choice to normalize leukocyte expression levels [52]. Cycle
threshold (c(t)) values were acquired with the Opticon Monitor
2.01 software (MJ Research) and using this information, we
subtracted the baseline signal as the average of the fluorescence
measured from cycle 1 to 40 and we set the c(t) line to a standard
deviation of 1.00. The normalized gene expression was calculated
using the Q-Gene software application [53], which does not
assume that the PCR amplification efficiencies of target and
reference genes are equivalent. Real-time PCR efficiencies (E)
were calculated by amplifying a series of 2-fold dilutions of each
factor. The mean c(t) values were plotted against the log of the
amount of cDNA added. The linear graphs obtained (correlation
coefficients.0.99) were used to calculate the corresponding E.
The mean normalized expression was given by calculating the
average c(t) values of the target and reference triplicates. Single
gene expression values and the comparison between groups are
shown in supplementary Table S1.
3. Validation of the new inferred links Freshly isolated
PBMCs, from a new set of 16 HC not previously used in the
network construction, were stimulated with 20 ng/ml recombi-
nant human IL10 (R&D Systems), 4 ng/ml recombinant human
IL4 (R&D Systems) or 40 ng/ml recombinant human CTLA4/Fc
chimera (R&D Systems) for 12 and 24 hours, or left unstimulated
as controls. At the end of the assay, RNA was isolated from the
cells and gene expression was measured by rtPCR as described
above.
4. In vitro Jagged1 validation assays Jagged1 validation
assays were performed using PBMC from patients with MS
untreated and stimulated in vitro with 20 mg/ml of human jagged1
peptide 188–204 (CDDYYYGFGCNKFCRPR; Sigma-Aldrich)
[33], or with 1.000 u/ml of recombinant human INF-b (PBL
Biomedical Laboratories) or both. Cells were incubated for 24 h
and RNA was extracted and quantified by real time PCR as
described before. KL-divergence values were calculated for each
group in the T-cell activation network as described above.
5. Experimental Autoimmune encephalomyelitis Female
C57B6 mice obtained from Charles River (6–8 weeks old; 20 gr.
body weight) were immunized in the lateral flank with a 100 ml
emulsion of saline and incomplete Freunds adjuvant containing
100 mg Myelin Olygrodendrocyte Glycoprotein (MOG35–55)
peptide from Sigma (Germany) supplemented with 4 mg/ml
Mycobacterium tuberculosis (H37Ra strain from Difco, Detroit, MI).
The animals were weighed on a daily basis and inspected for
clinical signs of experimental autoimmune encephalomyelitis
(EAE) by a blind observer as described previously [54]. Animals
were treated with 1 mg/day of human jagged1 peptide 188–204
(CDDYYYGFGCNKFCRPR; Sigma-Aldrich) [33] beginning at
the day of immunization until day 30 post-immunization. Disease
severity was assessed according to the following scale: 0 = normal;
1 = limp tail; 2 = mild paraparesis of the hind limbs, unsteady gait;
3 = moderate paraparesis, voluntary movements still possible;
4 = paraplegia or tetraparesis; 5 = moribund state. Data shown
for the EAE studies are representative of two independent
experiments performed with the number of animals indicated.
The University of Navarra Committee for Animal Care approved
the entire animal studies carried out.
Histological evaluation was performed on paraformaldehyde-
fixed, paraffin embedded sections of the brain and spinal cord, as
described previously [54]. Sections (10 mm thick) were stained with
haematoxylin and eosin (H&E) and with Luxol fast-blue to assess
inflammation and demyelination. We examined 20 consecutive
sagittal sections from each region examined (brain, cervical,
thoracic and lumbar spinal cord) of every animal in the study.
Semi-quantitative histological evaluation for inflammation and
demyelination was carried out and scored blindly using the
following scale: 0, normal; 1, 1-3/section perivascular cuffs with
minimal demyelination; 2, 3-10 perivascular cuffs/section accom-
panied by moderate demyelination; 3, widespread perivascular
cuffing, extensive demyelination with large confluent lesions.
6. Flow Cytometry analysis Cells were phenotyped by
three-colour flow cytometry (FACSaria) according to the
expression of CD25 and Foxp3 using the mouse regulatory T
cell staining kit from Ebiosciences, UK. We analyzed the
splenocytes from naı¨ve or treated C57B6 mice suffering EAE at
day 9 (n = 6 placebo and 6 Jagged1 treated mice) and day 30
(n = 24 placebo and 24 Jagged1 treated mice) postinjection (p.i.).
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7. ELISpot We assessed the secretion of IFN-c, IL-4 and IL-
17 in splenocytes from naı¨ve or treated C57B6 mice suffering EAE
at day 9 using the mouse-IFNc and mouse-IL4 ELISpot plus kit
from Mabtech (Mabtech, US), and the mouse-IL17 ELISpot from
Ebioscience (Ebioscience,UK) according to the manufacturer’s
instructions. Antigen stimulation was carried out with the
immunizing antigen (MOG35–55 100 mg/ml) for 48 h and we
used either PHA or ConA (5 mg/ml) as a positive control for Th1
and Th2, or for Th17, respectively. ELISpot quantification was
performed with the Immunospot S4 Pro Analyzer (Cellular
Technology Ltd, US).
Network Analysis
1. Ingenuity Pathways Knowledge Base analysis Because
Bayesian algorithms might provide several different results with
the same experimental dataset, feeding the algorithm with
a template of the network will diminish the number of different
outputs and increase their accuracy. Thus, in order to obtain
a template (structural network) of the gene network that controls the
T-cell activation, we used biological knowledge from co-expression
data available at the Ingenuity database, using the Ingenuity
Pathways Knowledge Base (Ingenuity Systems Inc. Redwood City,
USA). We were interested in evaluating five critical processes in T-
cell activation, namely: 1) antigen presentation and co-stimulation,
2) Th1 differentiation; 3) Th2 differentiation; 4) T regulatory
(Treg) function; and 5) migration to tissues. Genes were distributed
in five biological functions based in biological knowledge (Table
S2) as follows: 1) antigen presentation, signalling threshold
modulation and co-stimulation-HLA-DRA, HLA-DQB1,
PTPRC (CD45) and CD28; 2) Th1 differentiation-TBX21 (T-
bet), STAT1, IFNG, TNFA and IL12A; 3) Th2 differentiation-
GATA3, STAT6, IL4, JAG1; 4) Treg function-CTLA4, IL10,
TGFB1 and JAG1; and 5) Migration-ITGA4, ITGB1, ITGB7.
There is significant biological knowledge regarding each of these
genes and they have all been implicated in autoimmune diseases,
including MS (see supplementary Table S2 and S3).
2. Bayesian network algorithm Gene expression data from
MS patients and HC were made discrete in two intervals with the
same number of associated cases. To model the T-cell activation
network, we performed structural learning using a Tabu Search
[55], based on the experimental data and retaining the structure of
the network obtained in the Ingenuity database search described
above. Because the inference of the Bayesian network does not
accept network cycles, the structural network template was
introduced after manually curated the presence of such cycles by
changing the orientation of links in order to maintain the link and
avoid cycles. During this procedure, no links were removed. The
overall approach of the Tabu Search is to avoid entrainment in
cycles by forbidding or penalizing moves that, in the next iteration,
take the solution to points in the solution space previously visited
[55]. The Tabu Search algorithm constructs a graphic in which
the nodes represent the measured gene levels and the arcs
represent statistically meaningful relationships and the dependency
between these genes. A Tabu Search was performed using a tabu
list size of 10 and a structural complexity influence of 1. Bayesian
analysis was processed using the BayesiaLab 3.3 software (Bayesia
SA. Laval Cedex, France). The algorithm considered links as arcs
(links in which the orientation of the connection cannot be
changed without changing the probabilistic relations encoded) if
the available information allow the algorithm to define the
direction of the interaction, or as edges (links in which the
orientation can be inverted) if the algorithm was not able to
definitively confirm a unique direction for the interaction.
3. Qualitative analysis of the network We took advantage
of tools developed for metabolomics studies to assess the functional
consequences of the network topology [20, 21]. The Cell Net
Analysis (CNA) approach and CNA 6.0 software (Steffen Klamt,
Max-Planck Institute, Magdeburg, Germany) was used to measure
the overall network function since gene expression patterns could
be considered stable states. We first evaluated the dependence
matrix in order to assess the functional consistency of the
reconstructed network. We then identified the minimal cut sets
(MCS) [22] required for the loss of a defined cell function. The
concept of minimal cut sets has been introduced to study structural
fragility and to identify knock-out strategies in biochemical
reaction networks [22]. In this study, a MCS was defined as
a minimal set of interactions whose removal blocks cell function
(e.g. Th1 differentiation). We defined the maintenance of a given
function based on biological knowledge using logical rules as
follow: 1) Antigen presentation and co-stimulation: CD28 AND
PTPRC AND (HLA-DQB1 OR HLA-DRA) NOT (CTLA4 OR
JAG1OR (CTLA4 AND JAG1) OR IL10 OR TGFB1 OR (IL10
AND TGFB1) OR (CTLA4 OR JAG1 OR (CTLA4 AND JAG1)
AND (IL10 OR TGFB1 OR (IL10 AND TGFB1)))); 2) Th1
differentiation: INFG AND IL12A AND STAT1 AND TBX21
AND TNF NOT (IL4 AND STAT6 AND GATA3 AND JAG1);
3) Th2 differentiation: IL4 AND STAT6 AND GATA3 AND
JAG1 NOT (INFG AND IL12A AND STAT1 AND TBX21
AND TNF); 4) Treg function: CTLA4 OR JAG1OR (CTLA4
AND JAG1) OR IL10 OR TGFB1 OR (IL10 AND TGFB1) OR
(CTLA4 OR JAG1 OR (CTLA4 AND JAG1) AND (IL10 OR
TGFB1 OR (IL10 AND TGFB1))); 5) migration: ITGA4 AND
(ITGB1 OR ITGB7) (which builds the VLA4 or LPAM adhesion
molecule respectively). We then calculated the fragility of the
network by using the F coefficient [22], which is defined as the
inverse of the average value of the number of interactions
participating in a minimal cut set. Robustness is defined as 1–
fragility. The five T-cell activation functions described were
considered as outputs of the network.
4. Quantitative analysis of the network In order to
measure the weight of each link in the different conditions we
calculated the Kullback-Leibler divergence (KL-divergence) for
each link of the network using ten groups of samples for each
diagnosis, randomly constructed with half of the total samples for
each condition. The KL-divergence is a measure that can be used
to evaluate the differences between the probability distributions
represented by the network, both with the arc corresponding to
the relation and without this arc [56].
DKL PEQð Þ~
X
i
P ið Þlog P ið Þ
Q ið Þ
In this case, it is a measure of the mutual information between
the parent and the child node in the network. The KL-divergence
is a natural distance measure from a ‘‘true’’ probability
distribution P to an arbitrary probability distribution Q. Typically
P represents data, observations, or a precise calculated probability
distribution. The measure Q typically represents a theory, a model,
a description or an approximation of P.
Statistical analysis
The Shapiro-Wilk Test was carried out on each group to assess the
normal distribution. Those data groups that were not normal were
transformed to base-e-logarithm. We used the student-t test to
compare individual gene expression levels between MS patients
and HC, the influence of IFN-ß treatment in patients with MS,
KL-divergence values and gene expression in animal studies.
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Differences in the clinical course of EAE, histological scores,
ELISpot and flow cytometry studies were assessed with the Mann-
Whitney U test. The Bonferroni correction for multiple testing was
applied as required. For all tests p values of,0.05 were considered
as significant. Data was analyzed and processed using the SPSS
13.0 statistical package (SPSS Inc. Chicago, USA).
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0001222.s001 (0.11 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001222.s002 (0.20 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0001222.s003 (0.07 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0001222.s004 (0.08 MB
DOC)
Table S5
Found at: doi:10.1371/journal.pone.0001222.s005 (0.11 MB
DOC)
ACKNOWLEDGMENTS
We wish to thank Begon˜a Ferna´ndez-Dı´ez for her technical support.
Author Contributions
Conceived and designed the experiments: PV RP IM. Performed the
experiments: RP. Analyzed the data: PV RP JG JI JS IM. Contributed
reagents/materials/analysis tools: JG JI JS IM. Wrote the paper: PV RP
IM.
REFERENCES
1. Barabasi AL, Oltvai ZN (2004) Network biology: understanding the cell’s
functional organization. Nat Rev Genet 5(2): 101–113.
2. Lanzavecchia A, Sallusto F (2005) Understanding the generation and function of
memory T cell subsets. Curr Opin Immunol 17(3): 326–332.
3. Crabtree GR (1989) Contingent genetic regulatory events in T lymphocyte
activation. Science 243(4889): 355–361.
4. Hill N, Sarvetnick N (2002) Cytokines: promoters and dampeners of
autoimmunity. Curr Opin Immunol 14(6): 791–797.
5. Steinman L, Zamvil S (2003) Transcriptional analysis of targets in multiple
sclerosis. Nat Rev Immunol 3(6): 483–492.
6. Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev
Immunol 23: 683–747.
7. Germain RN (2001) The art of the probable: system control in the adaptive
immune system. Science 293(5528): 240–245.
8. Leon K, Faro J, Lage A, Carneiro J (2004) Inverse correlation between the
incidences of autoimmune disease and infection predicted by a model of T cell
mediated tolerance. J Autoimmun 22(1): 31–42.
9. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG (2005) Cellular and
genetic mechanisms of self tolerance and autoimmunity. Nature 435(7042):
590–597.
10. Segel LA, Bar-Or RL (1999) On the role of feedback in promoting conflicting
goals of the adaptive immune system. J Immunol 163(3): 1342–1349.
11. Melero I, Arina A, Chen L (2005) The many sounds of T lymphocyte silence.
Immunol Res 33(2): 135–147.
12. Kitano H, K O, T K, Y M, Csete M, et al. (2004) Metabolic Syndrome and
Robustness Tradeoffs. Diabetes 53(S3): S6–S15.
13. Kitano H (2007) A robustness-based approach to systems-oriented drug design.
Nat Rev Drug Discov 6(3): 202–210.
14. Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes,
inflammation, and neurodegeneration. Neuron 52(1): 61–76.
15. Jeong H, Mason SP, Barabasi AL, Oltvai ZN (2001) Lethality and centrality in
protein networks. Nature 411(6833): 41–42.
16. Styczynski MP SG (2005) Overview of computational methods for the inference
of gene regulatory networks. Computers & Chemical Engineering 29: 519–534.
17. Sachs K, Perez O, Pe’er D, Lauffenburger DA, Nolan GP (2005) Causal protein-
signaling networks derived from multiparameter single-cell data. Science
308(5721): 523–529.
18. Bansal M, Belcastro V, Ambesi-Impiombato A, di Bernardo D (2007) How to
infer gene networks from expression profiles. Mol Syst Biol 3: 78, Epub 2007 Feb
2013.
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The
Connectivity Map: using gene-expression signatures to connect small molecules,
genes, and disease. Science 313(5795): 1929–1935.
20. de la Fuente A, Brazhnik P, Mendes P (2002) Linking the genes: inferring
quantitative gene networks from microarray data. Trends Genet 18(8): 395–398.
21. Sontag E, Kiyatkin A, Kholodenko BN (2004) Inferring dynamic architecture of
cellular networks using time series of gene expression, protein and metabolite
data. Bioinformatics 20(12): 1877–1886.
22. Klamt S (2006) Generalized concept of minimal cut sets in biochemical
networks. Biosystems 83(2–3): 233–247.
23. Montalban X (2007) MS treatment: Postmarketing studies. J Neurol Sci.
24. Feldmann M, Brennan FM, Maini R (1998) Cytokines in autoimmune disorders.
Int Rev Immunol 17(1–4): 217–228.
25. Kang BY, Kim TS (2006) Targeting cytokines of the interleukin-12 family in
autoimmunity. Curr Med Chem 13(10): 1149–1156.
26. Peter HH, Warnatz K (2005) Molecules involved in T-B co-stimulation and B
cell homeostasis: possible targets for an immunological intervention in
autoimmunity. Expert Opin Biol Ther 5(Suppl 1): S61–71.
27. Roncarolo MG, Battaglia M, Gregori S (2003) The role of interleukin 10 in the
control of autoimmunity. J Autoimmun 20(4): 269–272.
28. Le Y, Yu X, Ruan L, Wang O, Qi D, et al. (2005) The immunopharmacological
properties of transforming growth factor beta. Int Immunopharmacol 5(13–14):
1771–1782, Epub 2005 Aug 1772..
29. Rice GP, Hartung HP, Calabresi PA (2005) Anti-alpha4 integrin therapy for
multiple sclerosis: mechanisms and rationale. Neurology 64(8): 1336–1342.
30. The Games Collaborative G (2006) Linkage disequilibrium screening for
multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in
Europeans. J Neuroimmunol 23: 23.
31. Osborne BA, Minter LM (2007) Notch signalling during peripheral T-cell
activation and differentiation. Nat Rev Immunol 7(1): 64–75, Epub 2006 Dec
2015..
32. Rutz S, Mordmuller B, Sakano S, Scheffold A (2005) Notch ligands Delta-like1,
Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper
cells. Eur J Immunol 35(8): 2443–2451.
33. Li L, Milner LA, Deng Y, Iwata M, Banta A, et al. (1998) The human homolog
of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells
through interaction with Notch1. Immunity 8(1): 43–55.
34. Hartwell LH, Hopfield JJ, Leibler S, Murray AW (1999) From molecular to
modular cell biology. Nature 402(6761 Suppl): C47–52.
35. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human
disease network. Proc Natl Acad Sci U S A.
36. Kitano H (2002) Computational systems biology. Nature 420(6912): 206–210.
37. Friedman N (2004) Inferring cellular networks using probabilistic graphical
models. Science 303(5659): 799–805.
38. Baecher-Allan C, Hafler DA (2006) Human regulatory T cells and their role in
autoimmune disease. Immunol Rev 212: 203–216.
39. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, et al. (2004) Instruction
of distinct CD4 T helper cell fates by different notch ligands on antigen-
presenting cells. Cell 117(4): 515–526.
40. Quelle FW, Shimoda K, Thierfelder W, Fischer C, Kim A, et al. (1995) Cloning
of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated
in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol
15(6): 3336–3343.
41. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and
plasmacytoid dendritic cell precursors. Annu Rev Immunol 23: 275–306.
42. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, et al. (2003)
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory
cell 1 phenotype. Nature 421(6921): 388–392.
43. Hayes AL, Smith C, Foxwell BM, Brennan FM (1999) CD45-induced tumor
necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-
dependent and nuclear factor-kappaB-independent. J Biol Chem 274(47):
33455–33461.
44. Liu ZG (2005) Molecular mechanism of TNF signaling and beyond. Cell Res
15(1): 24–27.
45. Kang BY, Kim E, Kim TS (2005) Regulatory mechanisms and their therapeutic
implications of interleukin-12 production in immune cells. Cell Signal 17(6):
665–673, Epub 2005 Jan 2015..
46. Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as
a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.
Proc Natl Acad Sci U S A 101 Suppl 2: 14599–14606.
Netowrk Analysis Autoimmunity
PLoS ONE | www.plosone.org 14 November 2007 | Issue 11 | e1222
47. Galimberti D, Bresolin N, Scarpini E (2004) Chemokine network in multiple
sclerosis: role in pathogenesis and targeting for future treatments. Expert Rev
Neurother 4(3): 439–453.
48. Neuhaus O, Archelos JJ, Hartung HP (2003) Immunomodulation in multiple
sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci
24(3): 131–138.
49. Stallwood Y, Briend E, Ray KM, Ward GA, Smith BJ, et al. (2006) Small
interfering RNA-mediated knockdown of notch ligands in primary CD4+ T cells
and dendritic cells enhances cytokine production. J Immunol 177(2): 885–895.
50. John GR, Shankar SL, Shafit-Zagardo B, Massimi A, Lee SC, et al. (2002)
Multiple sclerosis: re-expression of a developmental pathway that restricts
oligodendrocyte maturation. Nat Med 8(10): 1115–1121.
51. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald
Criteria’’. Ann Neurol 58(6): 840–846.
52. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 3(7): RE-
SEARCH0034, Epub 2002 Jun 0018.
53. Muller PY, Janovjak H, Miserez AR, Dobbie Z (2002) Processing of gene
expression data generated by quantitative real-time RT-PCR. Biotechniques
32(6): 1372–1374, 1376, 1378–1379.
54. Moreno B, Hevia H, Santamaria M, Sepulcre J, Munoz J, et al. (2006)
Methylthioadenosine reverses brain autoimmune disease. AnnNeurol 60:
323–334.
55. Glover F, Laguna M (1997) Tabu Search: Kluwer Academic Publishers.
56. Kullback S, Leibler RA (1951) On information and sufficiency. Annals of
Mathematical Statics 22: 79–86.
Netowrk Analysis Autoimmunity
PLoS ONE | www.plosone.org 15 November 2007 | Issue 11 | e1222
